Status:
COMPLETED
Dexmedetomidine Versus Ketofol for Moderate Sedation in Endoscopic Retrograde Cholangiopancreatography
Lead Sponsor:
Sindh Institute of Urology and Transplantation
Conditions:
Sedation
Eligibility:
All Genders
20-60 years
Phase:
PHASE4
Brief Summary
Patients were randomly divided into Dexmedetomidine or Ketofol for sedation. In patients who received Dexmedetomidine, a 2ml ampule of 100 ug/ml was diluted in 18 ml of normal saline, making a total v...
Detailed Description
Patients aged 20-60 years of any gender scheduled for elective ERCP were included. All these patients had American Society of Anesthesiologists (ASA) classification I or II. While those who were aller...
Eligibility Criteria
Inclusion
- Aged 20-60 years
- Any gender
- Scheduled for elective ERCP
- American Society of Anesthesiologists (ASA) classification I or II
Exclusion
- Allergic to dexmedetomidine, Ketofol, or related medications
- BMI over 36 kg/m2 (morbidly obese)
- History of stroke, renal impairment, chronic obstructive pulmonary disease, asthma, chronic liver disease, hypothyroidism, and congestive cardiac failure
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT06212401
Start Date
December 1 2021
End Date
June 30 2022
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sindh Institute of Urology and Transplantation
Karachi, Sindh, Pakistan, 74200